Antimicrobial Subscription Models - Rewarding Availability, not volume - Episode 7
Omar Ali and Adam Buckler explore one of the boldest experiments in innovative contracting: subscription models for antibiotics.
With rising antimicrobial resistance and a broken commercial model offering little reward for new drug development, payers like NHS England have pioneered subscription frameworks that pay for availability—not usage.
By delinking revenue from prescriptions, these models aim to restore incentives for pharmaceutical innovation in one of healthcare’s most urgent but neglected fields.
What we cover
Why the traditional antibiotic market discourages investment in new drug development
How NHS England’s subscription model guarantees predictable returns for innovators
The early results—and the risks—of shifting to a usage-independent revenue model
How subscription frameworks could evolve globally to fight antimicrobial resistance
Key Takeaways
Subscription models aim to fix broken incentives, not just manage budgets.
Decoupling revenue from volume allows for sparing use without penalizing manufacturers.
Clear frameworks, usage safeguards, and unmet-need prioritization are critical to success.
Disclaimer: This presentation is for educational and informational purposes only, and is not intended as legal or policy advice. This presentation is based on non-confidential intelligence. Views expressed by the speakers are personal opinions and should not be attributed to anyone else. No part of this presentation may be reproduced for commercial purposes without the express permission of Verpora.
Never miss an episode
Receive a single email each week with a direct link to the latest IC Fireside Chat— no spam, just the latest episode, straight to your inbox.
Watch Next
